Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics Inc. has received an optimistic adjustment in its revenue projections for zorevunersen, reflecting increased expectations of well-received uptake, with target revenue estimates rising from $22 to $32 for its anticipated FY28 launch. Data from Phase I/II studies indicate that zorevunersen may significantly reduce seizures while providing cognitive benefits, thereby supporting its potential for disease modification in Dravet syndrome and de-risking future Phase 3 trials. Additionally, should the FDA provide expedited approval for zorevunersen, there exists potential for further upside, with target estimates possibly reaching the low-$40s, enhancing the overall outlook for Stoke Therapeutics' market position.

Bears say

Stoke Therapeutics Inc's stock faces a negative outlook primarily due to concerns regarding the protection of its intellectual property, as the potential failure to secure or extend key patents could adversely impact the company's asset valuation and market success. Additionally, despite some promising developments, the company operates in a competitive landscape for Dravet syndrome treatments, where multiple therapies have already gained significant market share. Lastly, the bleak natural history of the disease, characterized by persistent cognitive and seizure challenges, adds to the uncertainty surrounding the efficacy and market adoption of the company's lead product, zorevunersen.

STOK has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 8 analysts, STOK has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.